Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7530.091 | 1.0531 | 1.0504 | 2.0794 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7530.091 | 0.5238 | 0.4655 | 2.0794 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7530.091 | 0.0080 | -0.8035 | 2.0794 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7530.091 | 0.0043 | -0.8541 | 2.0794 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7531.091 | 1.0043 | 1.0026 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7531.091 | 1.0798 | 1.0469 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7531.091 | 1.0320 | 1.0191 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7531.091 | 1.0573 | 1.0339 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7531.091 | 1.0769 | 1.0452 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7531.091 | 1.0845 | 1.0495 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7531.091 | 0.0605 | -0.1419 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7531.091 | 0.0031 | -0.6500 | 3.3140 | |
| SUM159PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7531.091 | 0.0007 | -0.7788 | 3.3140 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7532.091 | 0.9827 | 0.9633 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7532.091 | 1.0527 | 1.1121 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7532.091 | 1.0626 | 1.1332 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7532.091 | 1.0555 | 1.1182 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7532.091 | 1.0337 | 1.0717 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7532.091 | 0.9768 | 0.9506 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7532.091 | 0.4425 | -0.1588 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7532.091 | 0.0112 | -0.9830 | 0.9414 | |
| SUM185PE | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7532.091 | 0.0080 | -0.9881 | 0.9414 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7533.091 | 0.9603 | 0.8954 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7533.091 | 1.0523 | 1.1398 | 0.7547 | |
| SUM225CWN | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7533.091 | 0.9874 | 0.9668 | 0.7547 |